Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
48 hedge funds and large institutions have $19.4M invested in Viracta Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 10 closing their positions.
133% more call options, than puts
Call options by funds: $7K | Put options by funds: $3K
9% more capital invested
Capital invested by funds: $17.8M → $19.4M (+$1.63M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.1% less ownership
Funds ownership: 31.91% → 31.81% (-0.1%)
13% less funds holding
Funds holding: 55 → 48 (-7)
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
70% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$284K |
| 2 |
Jane Street
New York
|
+$56.8K |
| 3 |
TCOT
Trust Company of Toledo
Holland,
Ohio
|
+$50.9K |
| 4 |
B
Bailard
Foster City,
California
|
+$36.2K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$18.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$97.3K |
| 2 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$86.2K |
| 3 |
Two Sigma Investments
New York
|
-$82.2K |
| 4 |
William Blair & Company
Chicago,
Illinois
|
-$75.7K |
| 5 |
Two Sigma Advisers
New York
|
-$46K |
VIRX Hedge Fund Activity: Q1 2023 in Review
48 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q1 2023, worth a combined $19.4M — up 9.2% from $17.8M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of VIRX and 3 opened new positions — a net loss of 7 holders — while 12 trimmed existing stakes and 8 added.
The largest buyer was Rubric Capital Management (New York), adding an estimated $284K. The largest seller was Millennium Management, cutting an estimated $97.3K.
- 48 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q1 2023, down from 55 in Q4 2022.
- Funds reported $19.4M of Viracta Therapeutics, Inc. Common Stock stock for Q1 2023, up 9.2% quarter-over-quarter.
- 3 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q1 2023 and 10 closed out, a net change of -7 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q1 2023 was Rubric Capital Management (New York), an estimated $284K added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q1 2023 was Millennium Management, an estimated $97.3K sold.
Based on aggregated 13F filings for Q1 2023.